Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy

被引:66
|
作者
Chulpanova, Daria S. [1 ]
Kitaeva, Kristina V. [1 ]
Green, Andrew R. [2 ]
Rizvanov, Albert A. [1 ,2 ]
Solovyeva, Valeriya V. [1 ]
机构
[1] Kazan Fed Univ, Inst Fundamental Med & Biol, Kazan, Russia
[2] Univ Nottingham, Nottingham Breast Canc Res Ctr, Div Canc & Stem Cells, Sch Med,Biodiscovery Inst, Nottingham, England
基金
俄罗斯科学基金会;
关键词
cancer immunotherapy; cytokines; anticancer immune responses; immune cell markers; populations; tumor microenvironment; NATURAL-KILLER-CELLS; CD8(+) T-CELLS; COLONY-STIMULATING FACTOR; PLASMACYTOID DENDRITIC CELLS; GROWTH-FACTOR-BETA; TUMOR-INFILTRATING LYMPHOCYTES; IMMUNE CHECKPOINT BLOCKADE; PHASE-1; CLINICAL-TRIAL; CD56(BRIGHT) NK CELLS; STAGE IV MELANOMA;
D O I
10.3389/fcell.2020.00402
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cytokine-based immunotherapy is a promising field in the cancer treatment, since cytokines, as proteins of the immune system, are able to modulate the host immune response toward cancer cell, as well as directly induce tumor cell death. Since a low dose monotherapy with some cytokines has no significant therapeutic results and a high dose treatment leads to a number of side effects caused by the pleiotropic effect of cytokines, the problem of understanding the influence of cytokines on the immune cells involved in the pro- and anti-tumor immune response remains a pressing one. Immune system cells carry CD makers on their surface which can be used to identify various populations of cells of the immune system that play different roles in pro- and anti-tumor immune responses. This review discusses the functions and specific CD markers of various immune cell populations which are reported to participate in the regulation of the immune response against the tumor. The results of research studies and clinical trials investigating the effect of cytokine therapy on the regulation of immune cell populations and their surface markers are also discussed. Current trends in the development of cancer immunotherapy, as well as the role of cytokines in combination with other therapeutic agents, are also discussed.
引用
收藏
页数:24
相关论文
共 50 条
  • [41] Progress and future perspectives of cancer immunotherapy
    Kawakami, Yutaka
    ANNALS OF ONCOLOGY, 2022, 33 : S462 - S462
  • [42] Wnt/β-catenin-pathway as a molecular target for future anti-cancer therapeutics
    Dihlmann, S
    Doeberitz, MVK
    INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (04) : 515 - 524
  • [43] Mucins as anti-cancer targets: perspectives of the glycobiologist
    Brockhausen, Inka
    Melamed, Jacob
    GLYCOCONJUGATE JOURNAL, 2021, 38 (04) : 459 - 474
  • [44] Anti-cancer perspectives of resveratrol: a comprehensive review
    Anwar, Muhammad Junaid
    Altaf, Areeba
    Imran, Muhammad
    Amir, Muhammad
    Alsagaby, Suliman A.
    Abdulmonem, Waleed Al
    Mujtaba, Ahmed
    El-Ghorab, Ahmed H.
    Ghoneim, Mohammed M.
    Hussain, Muzzamal
    Jbawi, Entessar Al
    Shaker, Mohamed E.
    Abdelgawad, Mohamed A.
    FOOD AND AGRICULTURAL IMMUNOLOGY, 2023, 34 (01)
  • [45] Mucins as anti-cancer targets: perspectives of the glycobiologist
    Inka Brockhausen
    Jacob Melamed
    Glycoconjugate Journal, 2021, 38 : 459 - 474
  • [46] Nanomedicine-based cancer immunotherapy: recent trends and future perspectives
    Vinoth-Kumar Lakshmanan
    Shlok Jindal
    Gopinath Packirisamy
    Shreesh Ojha
    Sen Lian
    Ajeet Kaushik
    Abdulqadir Ismail M. Abdullah Alzarooni
    Yasser Abdelraouf Farahat Metwally
    Sadras Panchatcharam Thyagarajan
    Young Do Jung
    Salem Chouaib
    Cancer Gene Therapy, 2021, 28 : 911 - 923
  • [47] Nanomedicine-based cancer immunotherapy: recent trends and future perspectives
    Lakshmanan, Vinoth-Kumar
    Jindal, Shlok
    Packirisamy, Gopinath
    Ojha, Shreesh
    Lian, Sen
    Kaushik, Ajeet
    Alzarooni, Abdulqadir Ismail M. Abdullah
    Metwally, Yasser Abdelraouf Farahat
    Thyagarajan, Sadras Panchatcharam
    Jung, Young Do
    Chouaib, Salem
    CANCER GENE THERAPY, 2021, 28 (09) : 911 - 923
  • [48] Optogenetic immunoengineering to develop improved anti-cancer immunotherapy
    He, Lian
    Nhung Nguyen
    Han, Gang
    Huang, Yun
    Zhou, Yubin
    CANCER RESEARCH, 2017, 77
  • [49] p53 as a target for anti-cancer immunotherapy
    Chen, HL
    Carbone, DP
    MOLECULAR MEDICINE TODAY, 1997, 3 (04): : 160 - 167
  • [50] Anti-Cancer immunotherapy: Immunomodulating agents in clinical development
    Loirat, D.
    Le Tourneau, C.
    ONCOLOGIE, 2015, 17 (09) : 379 - 389